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SUMMARY 25 
Abundant evidences suggest that growth factors, contained in platelets alpha 26 
granules, may play a key role in the early stages of the muscle healing process 27 
with particular regard to the inflammatory phase. Although the contents of the 28 
platelet-rich plasma preparations have been extensively studied, the biological 29 
mechanisms involved as well as the systemic effects and the related potential 30 
doping implications of this approach are still largely unknown. The aim of the 31 
present study was to investigate whether local platelet-rich plasma 32 
administration may modify the levels of specific cytokines and growth factors 33 
both in treated muscle and bloodstream in rats. Additional aim was to 34 
investigate more deeply whether the local platelet-rich plasma administration 35 
may exert systemic effects analyzing contralateral lesioned but untreated 36 
muscles. The results of the present study showed that platelet-rich plasma 37 
treatment induced a modification of certain cytokines and growth factor 38 
levels in muscle but not in the bloodstream, suggesting that local platelet-rich 39 
plasma treatment influenced directly or, more plausibly, indirectly the 40 
synthesis or recruitment of cytokines and growth factors in the site of injury. 41 
Moreover, the observed modifications of cytokine and growth factor levels in 42 
contralateral injured but not treated muscles, strongly suggested a systemic 43 
effect of locally injected platelet-rich plasma. 44 
 45 
 46 
 47 
 48 
INTRODUCTION 49 
The repair response of the musculoskeletal tissue generally starts with the 50 
formation of a blood clot and the following degranulation of platelets, which 51 
release locally growth factors (GFs) and cytokines (1). This 52 
microenvironment results in chemotaxis of inflammatory cells as well as 53 
activation and proliferation of local progenitor cells. Alpha granules are 54 
storage units within platelets, which contain pre-packaged GFs in an inactive 55 
form. Abundant evidences suggest that GFs, contained in platelet alpha 56 
granules, may play a key role in the early stages of the healing process with 57 
particular regard to the inflammatory phase being able of modulating the 58 
recruitment, duplication, activation and differentiation of the cells involved in 59 
the healing process (2-6). The efficacy of those GFs should be, in theory, 60 
directly proportional to their local concentration. This hypothesis is at the 61 
base of the use of platelet-rich plasma (PRP) in several circumstances, all of 62 
them characterized by the need of activating, modulating, speeding up or 63 
ameliorating the process of tissue repair.  64 
With regard to sport medicine, doping related issues are still matter of debate 65 
when considering this therapeutic approach for the treatment of sport-related 66 
injuries, in particular because of the Insulin-like growth factor-1 (IGF-1) 67 
content in the platelets alpha granules as well as the blood manipulation 68 
procedures. With particular regard to the muscle injection of platelets derived 69 
GFs, several issues still need to be clarified. Assuming that this procedure, as 70 
it has been demonstrated by several studies, is able to ameliorate the muscle 71 
tissue repair processes, it is still unclear whether the locally injected 72 
concentrated amount of GFs may exert systemic effects. Indeed, although the 73 
contents of the PRP preparations themselves have been extensively studied 74 
(7-12), the biological mechanisms involved in treatment with PRP as well as 75 
its systemic effect with the related potential doping implications are largely 76 
unknown. With this regard, it has to be underlined that the World Anti-77 
Doping Agency (WADA) prohibited the use of intramuscular injection of 78 
PRP in the 2010 list (13), then allowing its use in the 2012 list (14). This 79 
modification has been introduced despite the suggested systemic effect of 80 
locally injected GFs described by some authors (7, 15). Banfi et al. measured 81 
the levels of some cytokines and GFs in the serum obtained from five male 82 
subjects 30 minutes, three hours and 24 hours after the treatment with PRP in 83 
order to evaluate the eventual systemic effect of this local injection. Authors 84 
reported significant modifications of Vascular Endothelial Growth Factor 85 
(VEGF), Epidermal Growth Factor (EGF) and Chemokine (C-C motif) 86 
Ligand 2 (CCL2) levels 30 minutes after the treatment followed by a gradual 87 
return near to basal values 24 hours after the injection (15). Wasterlain et al. 88 
measured the levels of some GFs in the serum obtained from 25 subjects 89 
treated with leukocyte-rich PRP (LR-PRP). Authors reported significant 90 
increases of Insulin-like Growth Factor 1 (IGF-1), basic Fibroblast Growth 91 
Factor  (bFGF) and VEGF levels following the local PRP injection (7). 92 
With the exception of these two studies, the possible systemic effect of 93 
locally injected PRP is largely unknown. Conceivably, the systemic effect 94 
should be studied observing whether the treatment with PRP is able to modify 95 
the healing process in contralateral, but untreated with PRP, injured muscle, 96 
as suggested by Borrione et al in a recent study (2).   97 
The aim of the present study was to investigate whether the local PRP 98 
administration may modify the levels of specific cytokines and GFs both in 99 
treated muscle and bloodstream. The hypothesis at the base of this 100 
speculation was that the injection of cytokines and GFs naturally present in 101 
platelets and included in the WADA prohibited list could generate an increase 102 
of normal function, strength and capacity in non injured muscles if a systemic 103 
effect is really present. 104 
 105 
MATERIALS AND METHODS 106 
Animals and Surgery 107 
Wistar male adult rats (n=60), 8-9 weeks old, weighing approximately 250g, 108 
were used. Twenty-seven animals were sacrificed 2 days after surgery: seven 109 
rats were subjected to muscle injury on the right flexor muscles and 110 
immediately treated with PRP (treated group: TR), eight animals, used as 111 
controls, were subjected to the same muscle injury and left untreated 112 
(untreated group: UT), seven rats were subjected to muscle injury in both 113 
anterior limbs: the right limb was treated with PRP while the injury on the left 114 
limb remained untreated (contralateral group: CL). Five rats, left untreated 115 
and uninjured, were used as controls (C). Twenty-five animals were 116 
sacrificed 5 days after surgery (seven treated, seven untreated, six 117 
contralaterals and five controls). Eight animals were analyzed 30 days after 118 
surgery (two treated, two untreated, two contralaterals and two controls). 119 
Animals were kept in cages in a room with controlled temperature and 120 
humidity, with light/dark cycle of 12/12h, and fed with food and water ad 121 
libitum. Animals underwent surgery under general anesthesia by 122 
intramuscular injection of tiletamine + zolazepam (Zoletil) 3mg/kg. The 123 
decision of treating all animals with Finadyne administered at a dose of 2.5 124 
mg/kg/12h, independently of the presence of signs of suffering, was 125 
determined by the intention of obtaining the same condition in the different 126 
experimental settings since the use of anti-inflammatory drugs may affect 127 
both the healing process and the first inflammatory response (16). The 128 
surgical procedures were performed with the aid of a surgical microscope 129 
(Zeiss OPMI7, Jena, Germany). A longitudinal incision was performed on the 130 
right arm (or both arms) from the elbow region to the wrist in order to access 131 
the flexor sublimis muscles of the upper joint of the fingers. The muscle was 132 
then injured transversely and medially using a scalpel. The wedge-shaped 133 
lesion had a length of approximately 3 mm, a width of 2 mm and a depth of 3 134 
mm. After the incision, the injury sites of the treated animals were 135 
immediately filled with PRP. The flexor muscles were withdrawn after 2, 5 or 136 
30 days and analyzed. Animals were daily monitored to assess their state of 137 
wellness, to prevent self-mutilation, skin ulcers, muscle contractures and 138 
suffering. All procedures were carried out in accordance with the Local 139 
Ethical Committee and the European Communities Council Directive of 24 140 
November 1986 (86/609/EEC). All procedures were approved by the local 141 
Animal Care Committee and supervised by a veterinary. 142 
Blood Collection and PRP preparation 143 
Blood was collected by intracardiac drawing. Briefly the needle (21G) was 144 
inserted at the base of the sternum at 20° angle just lateral of the midline. 3-145 
3.5 ml of blood were slowly aspirated in a syringe containing 1 ml of 3.8% 146 
sodium citrate as anticoagulant in order to avoid platelet activation and 147 
subsequent degranulation. Blood was then transferred in sterile tubes 148 
containing sodium citrate and underwent a first centrifugation at 220 g for 15 149 
minutes. The top layer plasma was transferred, in another sterile tube without 150 
anticoagulant. To objectively determine the number of platelets and 151 
investigate the presence of other cells, before proceeding with the second 152 
centrifugation, a complete blood count was performed using a cell counter 153 
ADVIA 2021 (Bayer, Leverkusen, Germany) on a small amount of the 154 
plasma layer obtained after the first spin centrifugation (platelets content: 155 
361.43±32.48 x10³/µl; white blood cells content: 0.01±0.082 x103/µL). A 156 
second centrifugation at 1270 g for 5 minutes allowed the platelets to fall to 157 
the bottom of the tube. The most of acellular plasma was removed and 158 
discarded. The pellet was re-suspended in 100 µL of plasma to obtain a 159 
concentration of 4 times greater than the initial condition. This platelets 160 
enriched preparation was activated with 20 µL of 10% calcium chloride 161 
(Braun, Melsungen, Germany, 1000 IE / ml CaCl2-2SG) room temperature 162 
and after jellification, immediately inserted through tweezers into the injured 163 
muscle of the same animals from which blood has been drawn. The wound 164 
was then sutured and washed with saline solution (17-18). 165 
Cytokines and growth factors  166 
Blood samples were collected before surgery and animal sacrifice. Muscle 167 
samples (200-300 mg) were lysed in RIPA buffer (25 mmol/L Tris-HCl pH 168 
7.6 , 150 mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS; 169 
Sigma Aldrich) supplemented with Halt™Protease Inhibitor Cocktail (Sigma 170 
Aldrich). Plasma and muscle tissue samples were analyzed by Milliplex plus 171 
kit (Millipore, Billerica, Massachusetts) to quantify the levels of the 172 
following 10 molecules: Granulocyte-colony stimulating factor (G-CSF), 173 
Granulocyte-macrophage colony-stimulating factor (GM-CSF), Epidermal 174 
growth factor (EGF), Tumor necrosis factor alpha (TNF-α), Interleukin 1 175 
alpha (IL1-α), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), 176 
Interleukin 10 (IL-10), Interleukin 13 (IL-13).  177 
Statistical analysis 178 
Cytokines and Growth factors data were analyzed by two-way ANOVA 179 
analysis. Multiple comparisons were further performed with Bonferroni‘s 180 
post hoc test. The effects of the time for each cytokines and growth factors in 181 
each experimental condition were analyzed by one-way ANOVA. Differences 182 
were considered statistically significant when p-value < 0.05. All data are 183 
presented as mean  ± SD. The little variation of number of rats in 2 day group 184 
and 5 day group depended by accidental deaths, probably caused by 185 
intracardiac drawing or anesthesia.  186 
 187 
         RESULTS 188 
Cytokines and growth factors analysis 189 
In blood samples, the levels of all the investigated molecules remained 190 
unmodified in all the experimental conditions as well as in all the time points 191 
considered (data not showed).   192 
IL-4, IL-6, IL-10, IL-1α, TNF-α and EGF showed significant modifications in 193 
treated and contralateral muscle samples. On the contrary, G-CSF, GM-CSF, 194 
IL-5 and IL-13 showed no modifications when compared to basal values. 195 
IL-4. At day 2, TR, CL and UT showed lower values in comparison to C. The 196 
reduction was statistically significant only in TR (Table I). At days 5 and 30, 197 
TR showed a significant increase of IL-4 levels when compared to C and UT 198 
(Table I) while cytokine values in CL and UT remained lower in comparison 199 
to C. The increase in time of IL-4 levels in TR was statistically significant 200 
(p<0.05, one way-ANOVA). 201 
The evaluation of data was supported by two-way ANOVA analysis that 202 
revealed significant effects for interaction (F=5.975; p<0.001), treatment 203 
(F=7.346; p<0.001) and time (F=8.064; p<0.001). 204 
IL-10.  2 days after surgery, IL-10 showed a significant peak in TR (Table I). 205 
The cytokine in CL showed a behavior similar to what observad in TR with 206 
higher values when compared to C, but the difference was not statistically 207 
significant. At 2 days, TR and CL values were higher in comparison to UT 208 
whereas UT showed lower values when compared to C (Table I).  209 
At day 5, IL-10 levels in TR and CL decreased showing values lower than C 210 
(significant difference in CL). UT continued to show values lower than C 211 
(Table I). 212 
Interestingly, IL-10 showed a trend, even if not statistically significant, 213 
toward a progressive increase in TR, CL and UT from day 5 to day 30 after 214 
surgery. Two-way ANOVA analysis showed significant effects for interaction 215 
(F=5.618; p<0.001), treatment (F=20.39; p<0.0001) and time (F=13.14; 216 
p<0.0001).  217 
IL-1α showed a significant peak level at day 2 in TR in comparison to all the 218 
other groups. UT showed values lower than C while CL revealed values 219 
similar to C (Table I). 220 
At 5 days after surgery, IL-1α levels decreased in TR maintaining otherwise 221 
higher values when compared to all the other groups (Table I). 222 
At day 30 IL-1α values in TR reached values found in C. The decrease of IL-223 
1α values from day 2 to day 30 was statistically significant (p<0.05, one way-224 
ANOVA). Two-way ANOVA analysis confirmed significant effects for 225 
interaction (F=49.17; p<0.001), treatment (F=146.0; p<0.0001) and time 226 
(F=30.40; p<0.0001).  227 
IL-6 showed a significant peak in TR and CL at day 2 when compared to C 228 
and UT respectively (Table I).  IL-6 values in UT did not differ from those 229 
observed in C. 230 
At day 5, the values in TR remained higher than in C and UT (Table I).  231 
At 30 days after surgery, the cytokine values in TR decreased showing values 232 
similar to all the other groups. The IL-6 decrease in TR and CL from day 2 to 233 
day 30 was statistically significant (p<0.05, one way-ANOVA). The 234 
evaluation of data was supported by two-way ANOVA analysis that showed 235 
significant effects for interaction (F=95.24; p<0.001), treatment (F=179.2; 236 
p<0.0001) and time (F=277.0; p<0.0001).   237 
At day 2, TNF-α showed UT levels lower than in C (p<0.05). At day 5 TNF-238 
α in TR was characterized by a significant peak level when compared to the 239 
other experimental groups. At day 30, UT, TR and CL presented values lower 240 
than in C (Table I). The variations in time of the values of TNF-α in TR and 241 
UT resulted significant (p<0.05, one way-ANOVA). Two-way ANOVA 242 
analysis showed significant effects for interaction (F=11.16; p<0.001), 243 
treatment (F=14.72; p<0.0001) and time (F=29.07; p<0.0001).  244 
EGF levels in all injured muscles were significantly lower when compared to 245 
C values in all considered time points. In particular, at  day 2  TR, CL and UT 246 
presented values lower than in C.  UT levels were higher than those observed 247 
in  TR and CL (Table 1). 248 
At day 5, the values detected in all injured muscles continued to remain lower 249 
than those observed in C without significant differences among them. These 250 
results were still present 30 days after surgery (Table I).   251 
The comparison between EGF values in time in TR and UT groups showed 252 
two different trends. The UT values at day 30 were lower than those observed 253 
at days 2 and 5 (p<0.01, one way-ANOVA). On the contrary, EGF values in 254 
TR presented a progressive increase in the same time interval (p<0.001, one 255 
way-ANOVA). Two-way ANOVA analysis confirmed significant effect for 256 
interaction (F=3.422; p<0.01), treatment (F=51.74; p<0.0001) but not for the 257 
time.  258 
 259 
DISCUSSION 260 
The results of the present study showed that PRP treatment induced a 261 
modification of certain cytokines and GFs in muscle but not in the 262 
bloodstream, suggesting that local PRP treatment influenced directly or, more 263 
plausibly, indirectly the synthesis or recruitment of cytokines and GFs in the 264 
site of injury. 265 
Since cytokines and GFs have a short half-life (15), we can hypothesize that 266 
cytokines and GFs present in the site of injury after 2, 5 and 30 days from 267 
PRP application, were not directly derived from PRP application (data 268 
confirmed by the absence of relevant data in bloodstream). Conceivably, the 269 
variation of cytokines and GFs concentration observed in muscles resulted 270 
from biosynthetic activity of other cells (e.g.macrophages/monocyte) 271 
recruited in the site of injury.  272 
Moreover, the observed modifications of cytokines and GFs levels in 273 
contralateral injured but not treated muscles, strongly suggested a systemic 274 
effect of locally injected PRP. Indeed, several of the analyzed molecules, 275 
namely IL-1α, IL-4, IL-6, IL-10, TNF-α and EGF, showed a different 276 
behavior in the three different experimental conditions: treated, untreated and 277 
contralateral. In particular IL-1α, IL-4, IL-6, IL-10 and TNF-α showed a 278 
significant modification 2 and 5 days after PRP treatment. 279 
The local increase of cytokines can be determined by different factors. It is 280 
known that muscle healing process progresses through a constant series of 281 
overlapping phases (degeneration and inflammation, regeneration, 282 
remodelling) resulting in the restoration of the anatomic continuity and 283 
function (19). The first stage usually starts with the formation of a blood clot 284 
followed by the degranulation of platelets that release locally GFs and 285 
cytokines. The following phases are controlled by complex and dynamic 286 
molecular mechanisms involving local and systemic factors interacting with 287 
many different cell types recruited to the site of injury from the surrounding 288 
tissues and/or circulation (1). Generally, during the acute phase, following a 289 
muscle injury, polymorphonucleated leukocyte are the most abundant cells 290 
presents in the lesion site (19-22) and they are replaced by monocytes within 291 
the first days. Monocytes are then activated into macrophages and involved in 292 
the proteolysis and phagocytosis of the necrotic material (19, 23, 24). 293 
Previous studies demonstrated that PRP treatment increases the leukocyte 294 
infiltration in the injured muscle (2). Conceivably, the higher concentration of 295 
macrophages in the muscles treated with PRP may easily explain the 296 
observed increased concentration of IL-1α, in the treated group (25, 26). 297 
These data were confirmed by a recent study carried out by our group in 298 
which it has been observed a significant increase of NF-κB-p65 at 2-day post-299 
injury. On the contrary, at 5-day post-injury, while in the PRP group the level 300 
of NF-κB-p65 was still significantly higher than in the C group, in the UT 301 
group the NF-κB-p65 protein returned to approximately the same level as in 302 
the C group. The trend of NF-κB-p65 was directly correlated to the IL-1α 303 
trend (18). 304 
The amplification and modulation of the first inflammatory phase induced by 305 
PRP treatment may also be explained by the observed reduction of IL-10 306 
levels following PRP injection. Indeed, the reduction of IL-10 levels results in 307 
an increased macrophage recruitment, enhancing consequently the 308 
inflammatory condition during the first 2 days following the treatment (27). 309 
The observed increase of IL-4 and TNF-α levels at day 5 is a direct 310 
consequence of the amplification of the early inflammatory response. Indeed, 311 
macrophages recruited in the site of injury are subsequently activated, 312 
producing additional chemoattractors, thus resulting in an increased leukocyte 313 
recruitment in the site of injury. Conceivably, when considering the short half 314 
life of these cytokines, it could be assumed that the observed increased levels 315 
of IL-4 and TNF-α at day 5 after PRP treatment is the result of the synthesis 316 
of these cytokines by the leukocytes recalled in the site of injury. This 317 
hypothesis may explain the persistence of high levels of cytokines until 30 318 
days after the treatment. Indeed, IL-4 is able to protect lymphoid cells from 319 
apoptosis (28, 29), thus favoring the persistence of the amplified 320 
inflammatory response. Furthermore, IL-6 levels were found increased only 321 
in treated and contralateral muscles but not in untreated samples. 322 
Conceivably, this finding supports the hypothesis of a stimulated IL-6 323 
production by infiltrating lymphocytes and excludes its lesioned muscle 324 
origin. This observation strongly supports the conclusions of previous studies 325 
indicating that PRP injection induces an amplification and modulation of the 326 
early inflammatory response resulting in an increase of the inflammatory 327 
infiltration in the site of injury, data further confirmed by present study (2, 328 
18). Indeed, changes in cytokine values were predominantly recorded at day 2 329 
and day 5 with gradual reduction at day 30 after surgery with the exception of 330 
IL-4 in treated group.  This evidence suggests that the inflammatory response 331 
in the treated group continued beyond 30 days after surgery, though to a 332 
lesser extent. 333 
The hypothesis of a possible systemic effect of locally injected PRP 334 
preparation was effectively also confirmed by the results of the present study 335 
since several analyzed molecules such as IL-10, IL-6, TNF-α and EGF in 336 
contralateral muscles showed an intermediate behavior between treated and 337 
untreated samples. The observation that none of the analyzed molecules 338 
showed any statistically significant modification in the bloodstream following 339 
PRP local administration reinforces the hypothesis that certain, not yet 340 
identified, locally produced molecule may exert systemic effects being able of 341 
modifying the inflammatory response of contralateral injured but not treated 342 
muscles. The peculiarity of this investigation was to analyze “contralateral” 343 
muscles (the same animal was injured on both limbs and only one was treated 344 
with PRP while the other, the contralateral one, was left untreated) and 345 
observe whether the treatment with locally injected PRP, may influence the 346 
healing process even far from the site of injury. The results obtained using 347 
this experimental model strongly suggested that local PRP treatment may 348 
influence inflammatory responses even far from the site of injection. When 349 
considering its application on athletes, no evidence supports the hypothesis of 350 
possible action on non injured muscles, thus excluding possible muscle 351 
performance enhancing properties. Certainly, the issue of the systemic effect 352 
of locally injected PRP preparation needs further investigations. 353 
In conclusion, the results of the present study confirmed that PRP treatment 354 
influences the early inflammatory phase of the healing process. This 355 
observation may have an immediate clinical translation. Indeed, the 356 
demonstrated modulation of the inflammatory response may explain the pain 357 
reduction usually observed after PRP administration and accounting for the 358 
early mobilization of the patients (30). Moreover, suggests that an early 359 
treatment after the injury may results in better clinical responses.     360 
In literature, PRP has been studied “in vitro “ and “in vivo” in the field of 361 
maxillofacial surgery and general surgery, and more recently in muscle and 362 
tendon healing but little is known about a possible systemic effect deriving by 363 
the local use of PRP. Further experimental studies are needed in order to 364 
understand the biological mechanisms at the base of the inflammatory process 365 
following the local treatment with PRP preparations, focusing on which 366 
mediators exert systemic effect. For example a microarray analysis could be 367 
useful to investigate how IL-1α, IL-4, IL-6, IL-10, TNF-α, EGF, IL-5 and IL-368 
13 expression could be modulated in muscles. The easy reproducibility 369 
achieved in this study has allowed us to create a solid foundation on which 370 
future studies will be carried out in order to deeply understand the molecular 371 
dynamics of the inflammatory process modulated by PRP administration. A 372 
potential limitation of the present study was represented by the low number of 373 
animals analyzed 30 days after surgery (2 animals in each experimental 374 
condition). These data should be considered the result of a pilot study carried 375 
out in order to obtain useful indications for future analysis aimed to analyze 376 
the long-term effects of PRP preparations.   377 
The little variation of number of rats in 2 day group and 5 day group depends 378 
by accidental deaths probably caused by intracardiac drawing or anesthesia.  379 
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Attachment 1. Cytokines and growth factors in bloodstream at 2, 5 and 30 days after surgery. 
 
IL-4 2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
IL-10 2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  <3.1 <3.1 <3.1 C  11.85±7.99 18.73±11.36 14.93±5.77 
UT  <3.1 <3.1 <3.1 UT  14±8.34 16.74±10.93 17.75±10.22 
TR  <3.1 <3.1 <3.1 TR  11.01±4.92 18.48±10.48 13.72±6.3 
CL  <3.1 <3.1 <3.1 CL  12.68±5.70 16.75±11.31 13.38±9.94 
 
IL-1α 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
IL-6 
pg/ml 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  < 6.1 <6.1 <6.1 C  72.33±34.5 75.32±12.01 109.24±50.5
7 UT  <6.1 <6.1 <6.1 UT  50.02±10.93 82.88±35.53 90.17±40.20 
TR  <6.1 <6.1 <6.1 TR  113.14±100.2
0 
117±12.73 108±45.12 
CL  <6.1 <6.1 <6.1 CL  97.59±80.90 58.30±21.48 112.41±19.2
2         
TNF-α 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
EGF 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  7.82±4.09 6.26±1.01 6.55±2.82 C  <0.17 <0.17 <0.17 
UT  4.47±2.89 5.80±1.62 4.65±1.22 UT  <0.17 <0.17 <0.17 
TR  7.39±5.34 6.51±0.01 7.36±3.76 TR  <0.17 <0.17 <0.17 
CL  7.34±1.18 4.61±1.41 6.06±0.64 CL  <0.17 <0.17 <0.17 
 
G-CSF 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
GM-CSF 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  < 2.61 < 2.61 < 2.61 C  < 6.73 < 6.73 < 6.73 
UT  < 2.61 < 2.61 < 2.61 UT  < 6.73 < 6.73 < 6.73 
TR  < 2.61 < 2.61 < 2.61 TR  < 6.73 < 6.73 < 6.73 
CL < 2.61 < 2.61 < 2.61 CL < 6.73 < 6.73 < 6.73 
 
IL-5 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
IL-13 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  < 8.67 < 8.67 < 8.67 C  <4.77 <4.77 <4.77 
UT  < 8.67 < 8.67 < 8.67 UT  <4.77 <4.77 <4.77 
TR  < 8.67 < 8.67 < 8.67 TR  <4.77 <4.77 <4.77 
CL < 8.67 < 8.67 < 8.67 CL <4.77 <4.77 <4.77 
Table I. Cytokines and growth factors in muscles at 2, 5 and 30 days after surgery. 
IL-4 2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
IL-10 2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  4.05±0.95 4.13±0.33 3.96±1.7 C  0.63±0.34 0.64±0.34 0.60±0.23 
UT 
(n=) 
2.30±0.61* 3.41±0.72 3.29±1.33 UT 
(n=) 
0.06±0.05** 0.02±0.01 0.30±0.03 
TR 
(n=) 
1.77±0.45* 6.24±1.92*## 7.06±2.78*## TR 
(n=) 
1.09±0.41**## 0.46±0.21 0.61±0.04 
CL 
(n=) 
3.45±0.61* 3.63±0.91      2.78±0.82 CL 
(n=) 
0.93±0.26*## 0.16±0.08* 0.29±0.17 
 
IL-1α 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
IL-6 
pg/ml 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C 0.96±0.21 0.74±0.24 1,2±0,20 C 6.08±2.17 6.07±3.1 5.99±1.9 
UT 
(n=) 
0.14±0.08 0.23±0.08 1,32±0,06 UT 
(n=) 
17.53±4.61 1.59±0.53 0.85±0.5 
TR 
(n=) 
6.66±1.33**## 3.41±0.51**## 1,27±0,07 TR 
(n=) 
327.02±40.9**## 165.22±65.11**## 0.69±0.43 
CL 
(n=) 
1.32±0.54 0.94±0.38 1,05±0,18 CL 
(n=) 
298.51±6.4**## 1.55±0.93** 0.47±0.39 
        
TNF-α 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
EGF 
 
2 days 
pg/ml 
5 days 
pg/ml 
30 days 
pg/ml 
C  0.11±0.03 0.10±0.03 0.12±0.02 C  1.66±0.05 1.66±0.07 1.65±0.06 
UT 
(n=) 
0.03±0.01* 0.09±0.03 0.02±0.02* UT 
(n=) 
1.19±0.12** 1.14±0.18** 0.88±0.07** 
TR 
(n=) 
0.13±0.03# 0.31±0.10**## 0.02±0.02* TR 
(n=) 
0.73±0.08**## 0.86±0.11** 1.16±0.11** 
CL 
(n=) 
0.09±0.05 0.14±0.08 0.06±0.02 CL 
(n=) 
0.79±0.13**## 0.94±0.12** 0.75±0.06** 
C: control group, UT: untreated group, TR: treated group, CL: contralateral group. 
Multiple comparison Bonferroni’s test: *p<0,05 vc C; **p<0,01 vs C; # p<0,05 vs UT; ## p<0,01 vs UT 
